Alnylam Pharma's total assets for Q3 2024 were $4.21B, an increase of 4.87% from the previous quarter. ALNY total liabilities were $4.17B for the fiscal quarter, a 3.99% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.